

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>			
IN AN APPLICATION (Use several sheets if necessary)			
		Docket Number: 30457.0013USWO	Application Number: 10/550,165
		Applicant: Paul Savage et al.	
		Filing Date: July 21, 2006	Group Art Unit: 1623

<b>U.S. PATENT DOCUMENTS</b>						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/G.K./	2005/0222048	10/06/2005	Tsuji et al.			
	2006/0211856	09/21/2006	Tsuji et al.			
	2005/0192248	09/01/2005	Tsuji et al.			
	2004/0166554	08/26/2004	Chamoles			
	2009/0047299	02/19/2009	Savage			
	2006/0019246	01/26/2006	Tsuji et al.			
	5,242,800	09/07/1993	Jimenez et al.			
	5,785,975	07/28/1998	Parikh			
	5,958,426	09/28/1999	Moreau et al.			
	6,417,167	07/09/2002	Maruyama et al.			
	6,610,835	08/26/2003	Liotta et al.			
/G.K./	6,635,622	10/21/2003	Tomiyama et al.			

<b>FOREIGN PATENT DOCUMENTS</b>						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES      NO
/G.K./	EP 0988860	03/29/2000	EP			
	EP 1016409	07/05/2000	EP			
	WO 99/33475	07/08/1999	PCT			
	WO 03/009812	02/06/2003	PCT			
	WO 03/105769	12/24/2003	PCT			
	WO 05/102049	11/03/2005	PCT			
	WO 06/029010	03/16/2006	PCT			
/G.K./	WO 07/050668	05/03/2007	PCT			

<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
/G.K./		BEAUDOIN, L. et al., "NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic beta cells," <i>Immunity</i> (2002) 17:725-736				
/G.K./		BENDELAC, A. et al., "Autoreactivity by design: innate B and T lymphocytes," <i>Natur. Rev. Immunol.</i> (2001)				

EXAMINER	/Ganapathy Krishnan/		DATE CONSIDERED	07/29/2009
EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>		Docket Number: 30457.0013USWO	Application Number: 10/550,165
IN AN APPLICATION (Use several sheets if necessary)		Applicant: Paul Savage et al.	
		Filing Date: July 21, 2006	Group Art Unit: 1623

/G.K./	1:177-186		
	BENDELAC, A. et al., "The biology of NKT cells," Ann. Rev. Immunol. (2007) 25:297-336		
	BENDELAC, A., "Nondeletional pathways for the development of autoreactive thymocytes," Nat. Immunol. (2004) 5:557-558		
	BROSSAY, L. et al., "Cutting edge: structural requirements for galactosylceramide recognition by CD1-restricted NK T cells," J. Immunol. (1998) 161(10):5124-5128		
	DAOUDI, J-M. et al., "New bicyclam-galcer analogue conjugates: synthesis and in vitro anti-HIV activity," Biorg. Med. Chem. Lett. (2004) 14:495-498		
	DE LIBERO, G. et al., "Self glycosphingolipids: new antigens recognized by autoreactive T lymphocytes," News Physiol. Sci. (2003) 18:71-76		
	European Office Action for Application No. 05810863.0 dated April 2, 2008 (4 pages)		
	FISCHER, K. et al., "Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells," Proc. Natl. Acad. Sci. USA (2004) 101:10685-10690		
	GOODMAN & GILMAN's The Pharmacological Basis of Therapeutics, Tenth Edition, Hardman and Limbird, editors, The McGraw-Hill Companies, Inc., New York, (2001) 54-56		
	GUMPERZ, J.E. et al., "Murine CD1d-restricted T cell recognition of cellular lipids," Immunity (2000) 12:211-221		
	GUPTA, R.K. et al., "Adjuvants - a balance between toxicity and adjuvanticity," Vaccine (1993) 11(3):293-306		
	HONEY, K. et al., "Thymocyte expression of cathepsin L is essential for NKT cell development," Nat. Immunol. (2002) 3:1069-1074		
	International Search Report and Written Opinion for Application No. PCT/US2005/031407 (13 pages)		
	ISLAM, I. et al., "Synthesis and antiviral activity of (2-((4-(3-((1-methylethyl)amino)-2-pyridyl)-1-piperazinyl)carbonyl)-1H-indo 1-5-yl) (BHAP) acylspingosine HIV reverse transcriptase inhibitors," Biorg. Chem. (1995) 23(4):499-511		
	KITAMURA, H. et al., "The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells," J. Exp. Med. (1999) 189:1121-1127		
	PARK, S.-H. et al., "Tissue-specific recognition of mouse CD1 molecules," J. Immunol. (1998) 160:3128-3134		
	PRIGOZY, T.J. et al., "Glycolipid antigen processing for presentation by CD1d molecules," Science (2001) 291:664-667		
	SMYTH, M.J. et al., "NKT cells - conductors of tumor immunity?" Curr. Opin. Immunol. (2002) 14(2):165-171		
	SMYTH, M.J. et al., "NKT cells and tumor immunity - a double-edged sword," Nature Immunology (2001) 1:459-460		
/G.K./	STANIC A.K. et al., "Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by Beta-D-glucosylceramide synthase deficiency," Proc. Natl. Acad. Sci. USA (2003) 100:1849-1854		

EXAMINER	/Ganapathy Krishnan/	DATE CONSIDERED	07/29/2009
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>		Docket Number: 30457.0013USWO	Application Number: 10/550,165
IN AN APPLICATION (Use several sheets if necessary)		Applicant: Paul Savage et al.	
		Filing Date: July 21, 2006	Group Art Unit: 1623

/G.K./		United States Office Action for Application No. 11/218,906 dated 11/10/2008 (8 pages)
		United States Office Action for Application No. 11/771,128 dated October 29, 2008 (14 pages)
		VAN DER VLIET, H.J.J. et al., "Effects of $\alpha$ -galactosylceramide (KRN7000), interleukin-12 and interleukin-7 on phenotype and cytokine profile of human Vo2+V $\beta$ 11+T cells," <i>Immunology</i> (1999) 98:557-563
		VANDOMMELLEN, S.L.H. et al., "Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells," <i>J. Virology</i> (2003) 77(3):1877-1884
		WINAU, F. et al., "Saposin C is required for lipid presentation by human CD1b," <i>Nat. Immunol.</i> (2004) 5:169-174
		WU, D.Y. et al., "Cross-presentation of disialoganglioside GD3 to natural killer T cells," <i>J. Exp. Med.</i> (2003) 198:173-181
		XIA, C. et al., "Thio-isoglobotrihexosylceramide, an Agonist for activating invariant natural killer T cells," <i>Org. Lett.</i> (2006) 8(24):5493-5496
		ZAJONC, D.M. et al., "Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity," <i>J. Exp. Med.</i> (2005) 202(11):1517-1526
		ZHOU, D. et al., "Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins," <i>Science</i> (2004) 303:523-527
		ZHOU, D., "The immunological function of iGb3," <i>Curr. Prot. Pept. Sci.</i> (2006) 7:325-333
/G.K./		



EXAMINER	/Ganapathy Krishnan/	DATE CONSIDERED	07/29/2009
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			